May 29, 2026
Colorado’s HB 26-1325 is the most significant expansion of the state’s natural medicine program since the Natural Medicine Health Act first became law.
The bill establishes an ibogaine research pilot program within the Behavioral Health Administration, creates a pathway to fully licensed ibogaine Healing Centers, and introduces a series of licensing and regulatory changes affecting operators across the natural medicine space.
Register for a live webinar on Thursday, June 4 at 1:30 p.m. MT to join Vicente attorneys who were directly involved in advancing HB 26-1325 and who bring years of experience in psychedelic law. They will break down what the legislation means in practice: from the pilot program’s structure and federal approval pathways to new licensing tools and the road to fully licensed ibogaine healing centers.
Topics include:
- Ibogaine research pilot program funding contingencies, federal approval requirements and site selection
- IND, Right-to-Try and DEA research registration pathways
- Limited Regulated Natural Medicine Sales Licensing and 280E implications for healing centers
- Temporary Premises Permits and zoning considerations
- Personal use changes and the close of disguised sales loopholes
- Mandatory Indigenous benefit-sharing requirements
You’ll hear from two of Vicente’s leading psychedelics attorneys:
- Joshua Kappel, Founding Partner — Co-author of Colorado’s Proposition 122, the Natural Medicine Health Act, and chair of the campaign committee for Natural Medicine Colorado. He served as interim Executive Director of Colorado for Ibogaine and was directly involved in drafting and advancing HB 26-1325. Ranked Band 1 for Psychedelics Law by Chambers and Partners USA, Josh advises clients on corporate structuring, the intersection of state and federal law, licensing, and regulatory compliance across the psychedelics space.
- Barine Majewska, Counsel — Leading member of Vicente LLP’s Psychedelics and Emerging Therapies Practice Group who brings firsthand research experience from psilocybin studies at the Johns Hopkins School of Medicine and focuses on the legal, ethical and regulatory frameworks shaping Colorado’s natural medicine program
